- Abstract Number: 1161
Gadolinium-Enhanced Magnetic Resonance Imaging in Shoulders Contributes Accurate Diagnosis and Predicting Recurrence to Patients with Polymyalgia Rheumatica
- Abstract Number: 1864
Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
- Abstract Number: 264
Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort
- Abstract Number: 2237
Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies
- Abstract Number: 1873
Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap
- Abstract Number: 577
Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients
- Abstract Number: 629
Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting
- Abstract Number: 2446
Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
- Abstract Number: 2484
Gender Influence on Treatment Effectiveness in Psoriatic Arthritis
- Abstract Number: 1866
Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues
- Abstract Number: 2023
Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways
- Abstract Number: 1952
Genes Associated with Nucleotide Oligomerization Domain-Like Receptor Signaling Pathway Are Upregulated in Discoid Lupus Erythematosus
- Abstract Number: 1004
Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis
- Abstract Number: 1932
Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease
- Abstract Number: 776
Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma
- Abstract Number: 2024
Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus
- Abstract Number: 1942
Genome-wide Association Study in a Japanese Population Revealed Novel Candidate Genes for Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Abstract Number: 1050
Genome-Wide DNA Methylation Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis
- Abstract Number: 1718
Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017
- Abstract Number: 2917
Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
- Abstract Number: 2658
Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries
- Abstract Number: 2670
Giant Cell Arteritis with Intracranial Vasculitis: A Case Series
- Abstract Number: 2659
Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study
- Abstract Number: 1995
Gingival-Derived Mesenchymal Stem Cells Alleviate Cartilage Damage in Collagen-Induced Arthritis via Suppressing Activities of Inflamed Synovial Fibroblast
- Abstract Number: L16
GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study
- Abstract Number: 416
Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
- Abstract Number: 1379
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
- Abstract Number: 1383
Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study
- Abstract Number: 1665
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
- Abstract Number: 1688
Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial
- Abstract Number: 2562
Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018
- Abstract Number: 1766
GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries
- Abstract Number: 2689
GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
- Abstract Number: 2876
Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Arthritis Patients
- Abstract Number: 1446
Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
- Abstract Number: 1477
Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as – Analysis of a Non-Interventional Study in Germany
- Abstract Number: 1087
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
- Abstract Number: 1499
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
- Abstract Number: 228
Good Pain, Bad Pain: Illness Perception and Physicians Attitude Towards Rheumatoid Arthritis and Fibromyalgia Patients
- Abstract Number: 1183
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
- Abstract Number: 356
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
- Abstract Number: 337
Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study
- Abstract Number: 331
Gout Management in the Medical Community: A Claims-Based Analysis
- Abstract Number: 1117
Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience
- Abstract Number: 872
Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry
- Abstract Number: 1668
Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry
- Abstract Number: 33
GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes
- Abstract Number: 2569
Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
- Abstract Number: 1494
Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
- Abstract Number: L13
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
- Abstract Number: 807
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
- Abstract Number: 2317
Gut Dysbiosis Is Associated with Measures of Early Vascular Dysfunction in Patients with Rheumatoid Arthritis
2019 ACR/ARP Annual Meeting
November 8-13, 2019 in Atlanta, GA